Phenothiazine ferroptosis inhibitor, preparation method therefor and application thereof
AssigneeChengdu Henghao Innovative Science and Technology Co., Ltd.
InventorsShengyong Yang, Linli Li
Life of this patent
Estimating the term…
Abstract
A phenothiazine ferroptosis inhibitor, a preparation method therefor and an application thereof. Specifically provided is a compound represented by formula I, or a salt thereof, or a stereoisomer thereof. The synthesized phenothiazine compound has a good inhibitory effect on ferroptosis and has good drug safety. Moreover, the compound can be used to prepare a ferroptosis inhibitor, and can also be used to prepare a drug for treating diseases related to ferroptosis, such as neurodegenerative diseases, tumors, tissue ischemia reperfusion injury, stroke, cardiovascular diseases, renal failure, and diabetic complications.
Claims9
A compound represented by formula IV, a salt thereof, or a stereoisomer thereof:
- wherein,
- ring B is selected from 5- to 6-membered unsaturated heterocyclyl independently substituted by n R2;
- n is an integer of 0˜3;
- each R2 is independently selected from substituted or unsubstituted C1˜C3 alkyl, halogen, amino, —C(O)NR3R4, —C(O)R5 and —C(O)OR5;
- or two R2 on the same carbon atom constitute ═O;
- R3 and R4 are independently selected from hydrogen, substituted C1˜C2 alkyl, and substituted aryl;
- R5 is independently selected from hydrogen and C1˜C2 alkyl;
- the substituent of the alkyl is selected from substituted or unsubstituted 5- to 6-membered saturated heterocyclyl, 4- to 6-membered saturated cycloalkyl, —NR6R7, aryl, naphthyl, and C1˜C3 alkoxy;
- R6 and R7 are independently selected from C˜C3 alkyl;
- the substituent of the saturated heterocyclyl is selected from C1˜C8 alkyl and —C(O) OR5;
- the substituent of the aryl is selected from C1˜C2 alkyl and nitro;
- and
- the heteroatom of the heterocyclyl is selected from N, O and S.
A compound represented by formula V, a salt thereof, or a stereoisomer thereof:
- wherein,
- R1 is selected from hydrogen and 4- to 6-membered saturated heterocyclyl;
- R2 is null, or R2 is selected from substituted or unsubstituted C1˜C3 alkyl, halogen, substituted or unsubstituted 4- to 6-membered saturated heterocyclyl, —C(O)NR3R4, —C(O)R5 and —C(O)OR5;
- R3 and R4 are independently selected from hydrogen, substituted or unsubstituted C1˜C3 alkyl, 4- to 6-membered saturated heterocyclyl, and substituted 4- to 5-membered unsaturated cycloalkyl;
- R5 is selected from hydrogen and C1˜C4 alkyl;
- the substituent of the alkyl is selected from substituted or unsubstituted 4- to 6-membered saturated heterocyclyl, 4- to 6-membered saturated cycloalkyl, —NR6R7, aryl, and naphthyl;
- R6 and R7 are independently selected from C1˜C2 alkyl;
- the substituent of the saturated heterocyclyl is selected from C1˜C4 alkyl and —C(O)OR5;
- the substituent of the unsaturated cycloalkyl is selected from C1˜C4 alkyl, nitro, halogen, hydroxyl;
- and
- the heteroatom of the heterocyclyl is selected from N, O and S.
A compound selected from the following group, a salt thereof, or a stereoisomer thereof:
Dependencies are inferred from the claim text.